Patient-friendly ovarian stimulation

Reproductive BioMedicine Online

Volumn 7, Issue 1, 2003, Pages 30-34

  Olivennes, François ^a  

^a Obstetric/Gynecology Department   (France)

Author keywords

Complications; GnRH antagonist; IVF; Stimulation

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE; ESTROGEN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LEUPRORELIN; TRIPTORELIN;

BIRTH RATE; CELL COUNT; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DESENSITIZATION; DRUG COST; DRUG MEGADOSE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INJECTION SITE; MULTIPLE PREGNANCY; OOCYTE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PREGNANCY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION;

EID: 0038148469     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61725-7     Document Type: Review

References (51)

1. Al-Inany H, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
2. Albano C, Smitz J, Camus M et al. 1997 Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility 67, 917-922.
3. Albano C, Felberbaum RE, Smitz J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Human Reproduction 15, 526-531.
4. Blondel B, Kaminski M 2002 Trends in the occurrence, determinants, and consequences of multiple births. Seminars in Perinatology 26, 239-249.
5. Chillik C, Acosta A 2001 The role of GnRH agonists and antagonists. Reproductive BioMedicine Online 2, 120-128.
6. Daya S, Gunby J, Hughes EG et al. 1995 Natural cycles for in-vitro fertilization: cost-effectiveness analysis and factors influencing outcome. Human Reproduction 10, 1719-1724.
7. Devreker F, Emiliani S, Revelard P et al. 1999 Comparison of two elective transfer policies of two embryos to reduce multiple pregnancies without impairing pregnancy rates. Human Reproduction 14, 83-89.
8. Diedrich K, Diedrich E, Santos E et al. 1994 Suppression of the endogenous LH-surge by the GNRH antagonist cetrorelix during ovarian stimulation Human Reproduction 9, 788-791.
9. Edwards R, Lobo R, Bouchard P et al. 1996 Time to revolutionize ovarian stimulation. Human Reproduction 11, 917-919.
10. Egbase PE 2000 Severe OHSS: how many cases are preventable? Human Reproduction 15, 8-10.
11. Emperaire JC, Ruffie A 1991 Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Human Reproduction 6, 506-510.
12. Engel JB, Ludwig M, Felberbaum R et al. 2002a Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Human Reproduction 17, 2022-2026.
13. Engel JB, Felberbaum RE, Eilers W et al. 2002b Clomiphene-induced LH surges and cetrorelix. Reproductive Biomedicine Online 5, 109-111.
14. ESHRE Capri Workshop Group 2000 Multiple gestation pregnancy. Human Reproduction 15, 1856-1864.
15. European and Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
16. European Orgalutran Study Group, Borm G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 15, 1490-1498.
17. Fauser BC, Devroey P, Yen SS et al. 1999 Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction 14, 2681-2686.
18. Fauser BC, de Jong D, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 87, 709-715.
19. Felberbaum R, Reissmann T, Kupker W et al. 1996 Hormone profiles under ovarian stimulation with human menopausal gonadotrophin HMG and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages. Journal of Assisted Reproduction and Genetics 13, 216-222.
20. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone Puregon. Human Reproduction 13, 3023-3031.
21. Gerris J, De Neubourg D, Mangelschots K et al. 2002 Elective single day 3 embryo transfer halves the twinning rate without decrease in the ongoing pregnancy rate of an IVF/ICSI programme. Human Reproduction 17, 2626-2631.
22. Gonen Y, Balakier H, Powell W, Casper RF 1990 Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 71, 918-922.
23. Howles C 2002 The place of gonadotrophin-releasing hormone antagonists in reproductive medicine. Reproductive BioMedicine Online 4 (suppl. 3), 64-71.
24. Ingerslev HJ, Hojgaard A, Hindkjaer J, Kesmodel U 2001 A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate. Human Reproduction 16, 696-702.
25. Itskovitz J, Boldes R, Levron J et al. 1991 Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertility and Sterility 56, 213-20.
26. Itskovitz J, Kol S, Mannaerts B 2000 Use a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimutation syndrome: preliminary report. Human Reproduction 15, 1965-1968.
27. Lenton EA, Cooke ID, Hooper M et al. 1992 In vitro fertilization in the natural cycle. Baillières Clinical Obstetrics and Gynæcology 6, 229-244.
28. Lewit N, Kol S, Manor D, Itskovitz-Eldor J 1996 Comparison of GnRH analogs and HCG for induction of ovulation and prevention of ovarian hyperstimulation syndrome OHSS: a case control study. Human Reproduction 11, 1399-1402.
29. Liu HC, Lai YM, Davis O et al. 1992 Improved pregnancy outcome with gonadotropin releasing hormone agonist (LHRH-a) stimulation is due to the improvement in oocyte quantity rather than quality. Journal of Assisted Reproduction and Genetics 9, 338-342.
30. Ludwig M, Felberbaum RE, Devroey P et al. 2000a Significant reduction of the incidence of ovarian hyperstimulation syndrome OHSS by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 264, 29-32.
31. Ludwig M, Schopper B, Katalinic A et al. 2000b Experience with the elective transfer of two embryos under the conditions of the German embryo protection law: results of a retrospective data analysis of 2573 transfer cycles. Human Reproduction 15, 319-324.
32. Ludwig M, Katalanic A, Diedrich K 2001 Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Archives of Gynecology and Obstetrics 265, 175-182.
33. Ludwig M, Felberbaum RE, Diedrich K, Lunenfeld B 2002 Ovarian stimulation: from basic science to clinical application. Reproductive BioMedicine Online 5 (suppl. 1), 73-86.
34. Nargund G, Waterstone J, Bland J et al. 2001 Cumulative conception and live birth rates in natural unstimulated IVF cycles. Human Reproduction 16, 259-262.
35. North American Ganirelix Study Group 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75, 38-45.
36. Nygren KG, Andersen AN 2002 Assisted reproductive technology in Europe, 1999. Results generated from European registers by ESHRE. Human Reproduction 17, 3260-3274.
37. Olivennes F 2000 Avoiding multiple pregnancies in ART. Double trouble: yes a twin pregnancy is an adverse outcome. Human Reproduction 15, 1663-1665.
38. Olivennes F, Frydman R 1998 'Friendly IVF' the way of the future? Human Reproduction 13, 1121-1124.
39. Olivennes F, Fanchin R, Bouchard P et al. 1994 The single or dual administration of the gonadotrophin-releasing hormone antagonist cetrorelix in an in vitro fertilization embryo transfer program. Fertility and Sterility 62, 468-476.
40. Olivennes F, Fanchin R, Bouchard P et al. 1995 Scheduled administration of GNRH antagonist cetrorelix on day 8 of in vitro fertilization cycles: a pilot study. Human Reproduction 10, 1382-1386.
41. Olivennes F, Fanchin R, Bouchard P et al. 1996 Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GNRH antagonist. Fertility and Sterility 66, 151-153.
42. Olivennes F, Alvarez S, Bouchard P et al. 1998 The use of a new GNRH antagonist cetrorelix in IVF-ET with a single dose protocol: a dose finding study of 3 versus 2 mg. Human Reproduction 13, 2411-2414.
43. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 2000 A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (cetrorelix) or a depot formula of a LH-RH agonist (triptoretin). Fertility and Sterility 73, 314-320.
44. Olivennes F, Cunha-Filho JS, Fanchin R et al. 2002 The use of GnRH antagonists in ovarian stimulation. Human Reproduction Update 8, 279-290.
45. Pelinck MJ, Hoek A, Simons AH, Heineman MJ 2002 Efficacy of natural cycle IVF: a review of the literature. Human Reproduction Update, 8, 129-139
46. Rongières-Bertrand C, Olivennes F, Righini C et al. 1999 Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotropin-releasing hormone antagonist cetrorelix: a pilot study with minimal stimulation. Human Reproduction 14, 683-688.
47. Staessen C, Nagy ZP, Liu J et al. 1995 One year's experience with elective transfer of two good quality embryos in the human invitro fertilization and intracytoplasmic sperm injection programmes. Human Reproduction 10, 3305-3312.
48. Tavaniotou A, Albano C, Smitz J, Devroey P 2002 Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertility and Sterility 77, 733-737.
49. Templeton A, Morris JK 1998 Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. New England Journal of Medicine 339, 573-577.
50. Vilska S, Tiitinen A, Hyden-Granskog C, Hovatta O 1999 Elective transfer of one embryo results in an acceptable pregnancy rate and eliminates the risk of multiple birth. Human Reproduction 14, 2392-2395.
51. Williams SC, Gibbons WE, Muasher SJ, Oehninger S 2002 Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertility and Sterility 78, 1068-1072.